CompletedPHASE1, PHASE2NCT03423186
A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients
Studying Sanfilippo syndrome type A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Paul Harmatz, MD, M.D., Ph.DChildrens's Hospital and Research Center Oakland
- Intervention
- SOBI003(drug)
- Enrollment
- 6 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2019
Study locations (4)
- Childrens's Hospital and Research Center, Oakland, California, United States
- University of North Carolina Hospitals, Chapel Hill, North Carolina, United States
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Gazi University Hospital, Ankara, Turkey (Türkiye)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03423186 on ClinicalTrials.govOther trials for Sanfilippo syndrome type A
Additional recruiting or active studies for the same condition.